Phase II DMSO Trial for Uncontrollable Intracranial Hypertension
Dimethyl-sulfoxide (DMSO) has received considerable attention for the treatment of a number of diseases of the Central Nervous System, including stroke, experimental head injury and spinal cord injury3,4,5,6. investigations into the intracranial pressure (ICP) reducing properties of this drug, and its effects on the injured brain, have been carried out over the last decade. De la Torre and his colleagues demonstrated in a primate brain injury model that ICP fell over a few minutes following the infusion of a 40 percent solution of DMSO4. Brown et al, showed in a missile model of penetrating head injury that DMSO improved cerebral perfusion pressure, cerebral blood flow and oxidative metabolism when compared to controls1. In a more recent abstract, Waller et al, reported that DMSO improved the control of ICP and potentially improved outcome in a series of patients suffering coma from acute severe head injury or from subarachnoid hemorrhage9. in a more recent publication, de la Torre et al, showed that doses of up to 4 g/kg/ day were well tolerated in primates with no evidence of long term toxicity7. This confirmed his previous observation that doses of up to 8 g/kg/day could be used without difficulty.
KeywordsIntracranial Hypertension Cerebral Perfusion Pressure Fluid Overload Spinal Cord Injury1 Acute Subdural Hematoma
Unable to display preview. Download preview PDF.
- 3.Mullan S, de la Torre JC, Kajihara K, Kawanaga HM: Use of dimethyl sulfoxide in experimental head and spinal cord injuries. J Neurol Neurosurg Pshychiat 36: 153–154 (1973).Google Scholar
- 5.De la Torre JC, Johnson CM, Goode DJ, Mullan S: Pharmacological treatment and evaluation of permanent spinal cord trauma. Neurology 25: 504–514 (1975).Google Scholar
- 9.Waller R, Camp PE, Tanave C, Paxton H: DMSO and neurosurgery. The DMSO Report Vol 1 (1) May (1981).Google Scholar